Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of pulmonary function testing on bleomycin dosing in germ cell tumours.
Roncolato FT, Chatfield M, Houghton B, Toner G, Stockler M, Thomson D, Friedlander M, Gurney H, Rosenthal M, Grimison P; Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP). Roncolato FT, et al. Intern Med J. 2016 Aug;46(8):893-8. doi: 10.1111/imj.13158. Intern Med J. 2016. PMID: 27305276 Clinical Trial.
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT, Joly F, O'Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F, Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M; GCIG Symptom Benefit group. Roncolato FT, et al. Oncologist. 2017 Sep;22(9):1117-1124. doi: 10.1634/theoncologist.2017-0047. Epub 2017 Jun 8. Oncologist. 2017. PMID: 28596446 Free PMC article.
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M. Roncolato FT, et al. Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.2017.10.019. Epub 2017 Oct 26. Gynecol Oncol. 2018. PMID: 29107348 Free article.
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).
Roncolato FT, O'Connell RL, Joly F, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Salutari V, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Fehm T, Ledermann J, Roemer-Becuwe C, Stockler MR, King MT, Friedlander ML. Roncolato FT, et al. Gynecol Oncol. 2020 Jan;156(1):45-53. doi: 10.1016/j.ygyno.2019.10.001. Epub 2019 Dec 10. Gynecol Oncol. 2020. PMID: 31836184
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Lee YC, King MT, O'Connell RL, Lanceley A, Joly F, Hilpert F, Davis A, Roncolato FT, Okamoto A, Bryce J, Donnellan P, Oza AM, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Feeney A, Kaminsky MC, Diamante K, Stockler MR, Friedlander ML; GCIG Symptom Benefit Group. Lee YC, et al. Among authors: roncolato ft. Int J Gynecol Cancer. 2022 Jun 6;32(6):761-768. doi: 10.1136/ijgc-2021-003142. Int J Gynecol Cancer. 2022. PMID: 35086926 Free PMC article.
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Campbell R, Costa DSJ, Stockler MR, Lee YC, Ledermann JA, Berton D, Sehouli J, Roncolato FT, Connell RO, Okamoto A, Bryce J, Oza AM, Avall-Lundqvist E, Berek JS, Lanceley A, Joly F, Hilpert F, Feeney A, Kaminsky MC, Diamante K, Friedlander ML, King MT; GCIG Symptom Benefit Group. Campbell R, et al. Among authors: roncolato ft. Gynecol Oncol. 2022 Aug;166(2):254-262. doi: 10.1016/j.ygyno.2022.05.024. Epub 2022 Jun 17. Gynecol Oncol. 2022. PMID: 35718565
Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice.
Campbell R, King MT, Stockler MR, Lee YC, Roncolato FT, Friedlander ML. Campbell R, et al. Among authors: roncolato ft. Patient Relat Outcome Meas. 2023 May 8;14:111-126. doi: 10.2147/PROM.S297301. eCollection 2023. Patient Relat Outcome Meas. 2023. PMID: 37188148 Free PMC article. Review.
13 results